134 related articles for article (PubMed ID: 37094966)
21. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
[TBL] [Abstract][Full Text] [Related]
22. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
24. Loss of Major Histocompatibility Complex Class I, CD8 + Tumor-infiltrating Lymphocytes, and PD-L1 Expression in Ovarian Clear Cell Carcinoma.
Lin SY; Hang JF; Lai CR; Chan IS; Shih YC; Jiang LY; Chang YH; Chen YJ
Am J Surg Pathol; 2023 Jan; 47(1):124-130. PubMed ID: 36221308
[TBL] [Abstract][Full Text] [Related]
25. Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status.
Whitehair R; Peres LC; Mills AM
Int J Gynecol Pathol; 2020 Nov; 39(6):558-566. PubMed ID: 31851060
[TBL] [Abstract][Full Text] [Related]
26. Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer.
Jäntti T; Luhtala S; Mäenpää J; Staff S
Tumour Biol; 2020 Nov; 42(11):1010428320971404. PubMed ID: 33169632
[TBL] [Abstract][Full Text] [Related]
27. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
[TBL] [Abstract][Full Text] [Related]
28. The relation of CD3, CD4, CD8 and PD-1 expression with tumor type and prognosis in epithelial ovarian cancers.
Arman Karakaya Y; Atıgan A; Güler ÖT; Demiray AG; Bir F
Ginekol Pol; 2021; 92(5):344-351. PubMed ID: 33914317
[TBL] [Abstract][Full Text] [Related]
29. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
30. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
Rosenbaum MW; Bledsoe JR; Morales-Oyarvide V; Huynh TG; Mino-Kenudson M
Mod Pathol; 2016 Sep; 29(9):1104-12. PubMed ID: 27198569
[TBL] [Abstract][Full Text] [Related]
32. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
33. Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer.
Høgdall E; Høgdall C; Vo T; Zhou W; Huang L; Marton M; Keefe SM; Busch-Sørensen M; Sørensen SM; Georgsen J; Mejlgaard E; Nedergaard L; Steiniche T
Int J Gynecol Cancer; 2020 Jul; 30(7):1034-1042. PubMed ID: 32527769
[TBL] [Abstract][Full Text] [Related]
34. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
35. Aligning digital CD8
Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F
Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
37. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
[TBL] [Abstract][Full Text] [Related]
38. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
[No Abstract] [Full Text] [Related]
39. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes.
Crumley S; Kurnit K; Hudgens C; Fellman B; Tetzlaff MT; Broaddus R
Mod Pathol; 2019 Mar; 32(3):396-404. PubMed ID: 30291344
[TBL] [Abstract][Full Text] [Related]
40. PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.
Bekos C; Pils D; Dekan S; Hofstetter G; Horak P; Reinthaller A; Polterauer S; Schwameis R; Aust S
Sci Rep; 2021 Mar; 11(1):6400. PubMed ID: 33737722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
